AMEX:CTEK CynergisTek, Inc. | 2.25 - |
NASDAQ:PMD Psychemedics Corporation | 7.25 +0.07 (+0.97%) |
NYSE:GEN Genesis Healthcare Inc | 0.48 0.00+0.25%) |
Trading Statistics | (Market Close Mar 5, 2021) |
---|---|
Market Cap | 62.06 M |
Outstanding Stock | 31.28 M |
Dividend | 0.00 |
Dividend Yield | 0.00 |
EPS | -2.09 |
YTD Change | 136.30% |
52 Week's Range | 0.45 - 41.36 |
Key Ratio & Margins | (Market Close Mar 5, 2021) |
---|---|
Price/Earning | -2.41 |
Price/Book Value | 6.03 |
Price/Sales | 0.33 |
ROA | - |
ROE | - |
Debt/Equity | 56.63 |
Business Information | |
---|---|
Capital Senior Living Corporation | |
Sector | Health Care |
Industry | Health Care Providers & Services |
Exchange | NYSE |
Key Fundamentals | (Market Close Mar 5, 2021) | |||
---|---|---|---|---|
CSU | CTEK | PMD | GEN | |
Market Cap | 62.06 M | 23.84 M | 40.07 M | 79.83 M |
Revenue Growth | - | - | - | - |
Net Income Growth | - | - | - | - |
Profit Margin | -13.70% | 38.90% | 8.90% | -3.10% |
P/E Ratio | -2.41 | 2.19 | 15.77 | -0.86 |
Price to Sales Ratio | 0.33 | 0.98 | 1.39 | 0.03 |
Price to Book Ratio | 6.03 | 2.24 | 4.66 | -0.14 |
Enterprise Value to EBITDA | 20.41 | 8.86 | 7.84 | 11.07 |
ROA | - | 38.00% | 13.80% | -3.30% |
ROE | - | 65.90% | 19.10% | 14.00% |
Debt/Equity | 56.63 | 1.63 | 0.33 | -4.71 |
Asset Turnover Ratio | 0.37 | 0.98 | 1.56 | 1.04 |
Current Ratio | 0.86 | 1.52 | 3.42 | 0.96 |
Dividend Yield | 0.00 | 0 | 7.10% | 0 |
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
---|---|---|---|---|
Revenue | 460.02 M | 467.00 M | 447.45 M | 412.18 M |
Cost Of Revenue | 351.21 M | 347.09 M | 335.62 M | 309.95 M |
Gross Profit | 108.81 M | 119.90 M | 111.83 M | 102.23 M |
Selling General & Administrative Expenses | 26.96 M | 23.57 M | 23.67 M | 20.35 M |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Income | 7.60 M | 7.84 M | 14.39 M | 18.84 M |
Net Income | -53.60 M | -44.17 M | -28.02 M | -14.28 M |
EPS | -1.80 | -1.50 | -0.97 | -0.50 |
Diluted EPS | -1.80 | -1.50 | -0.97 | -0.50 |
Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | |
---|---|---|---|---|
Revenue | 113.13 M | 114.18 M | 115.10 M | 115.65 M |
Cost Of Revenue | 88.67 M | 89.64 M | 87.83 M | 90.27 M |
Gross Profit | 24.46 M | 24.54 M | 27.26 M | 25.38 M |
Selling General & Administrative Expenses | 6.64 M | 7.57 M | 9.64 M | 5.59 M |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Income | 203,000.00 | 1.97 M | -3.12 M | 1.70 M |
Net Income | -12.53 M | -12.98 M | -26.29 M | -11.09 M |
EPS | -0.41 | -0.43 | -0.88 | -0.37 |
Diluted EPS | -0.41 | -0.43 | -0.88 | -0.37 |
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
---|---|---|---|---|
Total Current Assets | 73.46 M | 64.05 M | 82.03 M | 97.27 M |
Cash & Cash Equivalents | 44.32 M | 31.02 M | 47.32 M | 69.25 M |
Total Assets | 1.15 B | 1.18 B | 1.15 B | 1.02 B |
Total Current Liabilities | 85.03 M | 87.00 M | 81.39 M | 70.54 M |
Total Liabilities | 1.11 B | 1.10 B | 1.03 B | 883.29 M |
Shareholder's Equity | 35.27 M | 80.43 M | 116.92 M | 135.75 M |
Outstanding Stock | 31.28 M | 30.47 M | 29.99 M | 29.52 M |
Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | |
---|---|---|---|---|
Total Current Assets | 62.96 M | 62.94 M | 73.46 M | 51.95 M |
Cash & Cash Equivalents | 34.75 M | 35.22 M | 44.32 M | 22.72 M |
Total Assets | 1.33 B | 1.34 B | 1.15 B | 1.14 B |
Total Current Liabilities | 117.64 M | 110.68 M | 85.03 M | 83.99 M |
Total Liabilities | 1.30 B | 1.31 B | 1.11 B | 1.08 B |
Shareholder's Equity | 23.04 M | 33.94 M | 35.27 M | 59.73 M |
Outstanding Stock | 31.12 M | 31.32 M | 31.28 M | 31.18 M |
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
---|---|---|---|---|
Net Cash Flow from Operations | 36.87 M | 55.59 M | 52.28 M | 48.90 M |
Capital Expenditures | -21.97 M | -39.96 M | -62.37 M | -42.43 M |
Net Cash Flow from Investing Activities | -21.91 M | -124.94 M | -201.05 M | -161.43 M |
Net Cash Flow from Financial Activities | -1.67 M | 53.05 M | 126.85 M | 129.41 M |
Free Cash Flow | 14.91 M | 15.64 M | -10.09 M | 6.47 M |
Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | |
---|---|---|---|---|
Net Cash Flow from Operations | 1.90 M | 55.59 M | 52.28 M | 48.90 M |
Capital Expenditures | -4.46 M | -3.35 M | -4.01 M | -7.15 M |
Net Cash Flow from Investing Activities | 429,000.00 | -3.35 M | -3.98 M | -7.13 M |
Net Cash Flow from Financial Activities | -2.79 M | -4.61 M | 15.58 M | -6.24 M |
Free Cash Flow | -2.56 M | -4.50 M | 5.99 M | 4.61 M |
Key Ratios | (Market Close Mar 5, 2021) | |||
---|---|---|---|---|
Valuation Ratios | 2021 | 2020 | 2019 | 2018 |
P/E Ratio | -2.41 | -2.02 | -3.78 | -8.35 |
Price to Sales Ratio | 0.33 | 0.26 | 0.44 | 0.61 |
Price to Book Ratio | 6.03 | 5.11 | 4.12 | 4.54 |
Enterprise Value to EBIT | -245.00 | 179.00 | 92.00 | 59.00 |
Enterprise Value to EBITDA | 20.41 | 18.83 | 17.92 | 17.52 |
Profitability Ratios | 2021 | 2020 | 2019 | 2018 |
Revenue Growth | - | - | - | - |
Net Income Growth | - | - | - | - |
ROA | - | - | - | -4.70% |
ROE | - | - | - | -89.70% |
Liquidity Ratios | 2021 | 2020 | 2019 | 2018 |
Working Capital | -11.57 M | -22.95 M | 638,000.00 | 26.73 M |
Current Ratio | 0.86 | 0.74 | 1.01 | 1.38 |
Efficiency & Capital Structure Ratios | 2021 | 2020 | 2019 | 2018 |
Debt Equity Ratio | 56.63 | 13.70 | 8.80 | 6.51 |
Asset Turnover Ratio | - | - | - | 0.40 |
Symbol | Last Price | Change |
---|---|---|
Empty Scratchpad |